- ≥99% HPLC purity
- Lot-matched certificate of analysis
- Ships next business day, tracked
Tesamorelin (Egrifta-type) — Prescription Reference
GHRH(1–44) analogue, pharmaceutical grade — prescription-only reference listing
- Mol. weight5,135.86 g/mol
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
Prescription-only reference listing. This entry describes the pharmaceutical-grade, approved formulation of tesamorelin — the Egrifta family of products — rather than research-grade material. It appears in this institutional catalogue so that clinics and pharmacies can identify the molecule, its single approved indication, its presentation and its storage requirements. Product is supplied only against a valid prescription or documented institutional authorisation, and no dosing, administration or sourcing guidance appears on this page.
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone, retaining the full 44-residue GHRH sequence with a trans-3-hexenoyl group attached to the N-terminal tyrosine. That acyl cap sits at the site where dipeptidyl peptidase-4 cleaves native GHRH, and it is the structural basis for the molecule's improved stability. Supplied as the acetate salt, the peptide has a molecular weight of 5,135.86 g/mol and the formula C221H366N72O67S.
Specifications
Identity
- CAS number
- 218949-48-5
- Molecular formula
- C221H366N72O67S
- Molecular weight
- 5,135.86 g/mol
- Peptide class
- Growth hormone-releasing hormone (GHRH) analogue; growth hormone secretagogue
Additional detail
- Regulatory status
- Prescription-only medicine (Rx); supplied solely against valid prescription or institutional authorisation
- Generic name
- Tesamorelin acetate
- Approved brand family
- Egrifta, Egrifta SV and Egrifta WR formulations
- Structure
- Full 44-residue human GHRH sequence with a trans-3-hexenoyl group on the N-terminal tyrosine
- Molecular target
- GHRH receptor on anterior pituitary somatotrophs
- Downstream marker
- Endogenous pulsatile growth hormone release, with a consequent rise in IGF-1
- Approved indication
- Reduction of excess abdominal fat in adults with HIV infection and lipodystrophy
- Reference size listed
- 2 mg vial × 30
- Storage
- Per the approved labelling for the specific formulation — some presentations require 2–8 °C refrigeration, later reformulations are stable at controlled room temperature; reconstituted solution used per labelling
Questions about Tesamorelin (Egrifta-type) — Prescription Reference
Is tesamorelin available without a prescription?
No. The pharmaceutical formulation described here is a prescription-only medicine. This page is a reference listing in an institutional catalogue, covering identity, pharmacology, approved indication and storage; product is supplied only against a valid prescription or documented institutional authorisation, and no supply route is offered here.
How does it differ from growth hormone itself?
Tesamorelin acts upstream. It is a GHRH receptor agonist on pituitary somatotrophs, so growth hormone is released from the patient's own pituitary in a pulsatile pattern that remains subject to IGF-1 and somatostatin feedback. Somatropin is exogenous growth hormone administered directly, bypassing that regulatory loop.
What does the trans-3-hexenoyl group do?
It caps the N-terminal tyrosine of the full 44-residue GHRH sequence, at the position where dipeptidyl peptidase-4 cleaves and inactivates native GHRH. The hydrophobic group sterically hinders that cleavage while leaving the receptor-binding region of the peptide unchanged, which is the basis of the molecule's improved stability.
How is this different from the research-grade tesamorelin listing?
Same active molecule, different product and different status. The research listing covers lyophilised peptide supplied to laboratories under research-use-only terms with HPLC purity and a certificate of analysis. This entry covers the approved medicinal product, made under pharmaceutical quality systems and dispensed only on prescription. They are not interchangeable.
Why do storage instructions vary between presentations?
Because the formulation has been revised over time. Earlier vial presentations required refrigeration at 2–8 °C, while later reformulations were developed for stability at controlled room temperature, with different reconstitution volumes and vial strengths. The approved labelling for the specific product on hand is the governing reference.
Related
